financetom
Business
financetom
/
Business
/
Solventum Q4 Adjusted Earnings Fall, Sales Rise; 2025 Outlook Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Solventum Q4 Adjusted Earnings Fall, Sales Rise; 2025 Outlook Set
Feb 27, 2025 1:40 PM

04:23 PM EST, 02/27/2025 (MT Newswires) -- Solventum ( SOLV ) reported Q4 adjusted diluted earnings late Thursday of $1.41, down from $2.17 a year earlier.

Analysts polled by FactSet expected $1.31.

Net sales for the quarter ended Dec. 31 was $2.07 billion, up from $2.04 billion a year earlier.

Analysts surveyed by FactSet expected $2.05 billion.

The company said it expects full-year 2025 adjusted earnings of $5.45 to $5.65 per share. Analysts polled by FactSet expect $5.60.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Music publishers fend off Anthropic's bid to dismiss some AI copyright claims
Music publishers fend off Anthropic's bid to dismiss some AI copyright claims
Oct 6, 2025
Oct 6 (Reuters) - Artificial intelligence company Anthropic lost a bid on Monday to dismiss parts of a copyright infringement lawsuit brought by music publishers over Anthropic's alleged misuse of their song lyrics in its AI training. U.S. District Judge Eumi Lee ruled that Universal Music Group , Concord and ABKCO can continue pressing their claims that Anthropic enabled its...
Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices
Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices
Oct 6, 2025
Amgen Inc. ( AMGN ) on Monday launched AmgenNow, a new direct-to-patient program starting with Repatha (evolucumab). AMGN stock is trending lower. View the charts here. This follows results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial. In support of...
Why Is Arcus Biosciences Stock Trading Higher On Monday?
Why Is Arcus Biosciences Stock Trading Higher On Monday?
Oct 6, 2025
In the relentless quest for groundbreaking cancer therapies, innovative drug trials are reshaping treatment landscapes and redefining patient hope. Arcus Biosciences Inc. ( RCUS ) on Monday announced new monotherapy data for casdatifan in late-line metastatic clear cell renal cell carcinoma (ccRCC). ARC-20 is a Phase 1/1b dose-escalation and expansion study with four monotherapy cohorts (n=121): 50mg twice daily (BID),...
Delek US Reportedly Sues Marex Group, BTX Energy Over Contaminated Crude Oil
Delek US Reportedly Sues Marex Group, BTX Energy Over Contaminated Crude Oil
Oct 6, 2025
02:24 PM EDT, 10/06/2025 (MT Newswires) -- Delek US Holdings ( DK ) filed a lawsuit against Marex Group ( MRX ) and BTX Energy, alleging its El Dorado refinery in Arkansas took delivery of contaminated crude oil from the companies, resulting in more than $30 million in damages, according to media reports citing the complaints. Marex ( MRX )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved